These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19888795)

  • 21. Are health workers reduced to being drug dispensers of antiretroviral treatment? A randomized cross-sectional assessment of the quality of health care for HIV patients in northern Uganda.
    Seeberger UG; Valadez JJ
    Health Policy Plan; 2019 Oct; 34(8):559-565. PubMed ID: 31408152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term cost-effectiveness of home versus clinic-based management of chronic heart failure: the WHICH? study.
    Maru S; Byrnes JM; Carrington MJ; Stewart S; Scuffham PA
    J Med Econ; 2017 Apr; 20(4):318-327. PubMed ID: 27841726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study.
    Ganguli A; Wang J; Gourley DR
    Res Social Adm Pharm; 2012; 8(2):157-65. PubMed ID: 21712147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.
    Bourbeau J; Granados D; Roze S; Durand-Zaleski I; Casan P; Köhler D; Tognella S; Viejo JL; Dal Negro RW; Kessler R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():645-657. PubMed ID: 30936689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Annual cost of antiretroviral therapy among three service delivery models in Uganda.
    Vu L; Waliggo S; Zieman B; Jani N; Buzaalirwa L; Okoboi S; Okal J; Borse NN; Kalibala S
    J Int AIDS Soc; 2016; 19(5 Suppl 4):20840. PubMed ID: 27443270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness Analysis of Family Planning Services Offered by Mobile Clinics versus Static Clinics in Assiut, Egypt.
    Al-Attar GST; Bishai D; El-Gibaly O
    Afr J Reprod Health; 2017 Mar; 21(1):30-38. PubMed ID: 29595023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of implementing the chronic care model for HIV care in Uganda.
    Broughton EI; Muhire M; Karamagi E; Kisamba H
    Int J Qual Health Care; 2016 Dec; 28(6):802-807. PubMed ID: 27655788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modifications to ART service delivery models by health facilities in Uganda in promotion of intervention sustainability: a mixed methods study.
    Zakumumpa H; Bennett S; Ssengooba F
    Implement Sci; 2017 Apr; 12(1):45. PubMed ID: 28376834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis.
    Uthman RT; Sutton AJ; Jackson LJ; Uthman OA
    PLoS One; 2018; 13(1):e0191465. PubMed ID: 29360841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.
    Kulasingam S; Connelly L; Conway E; Hocking JS; Myers E; Regan DG; Roder D; Ross J; Wain G
    Sex Health; 2007 Sep; 4(3):165-75. PubMed ID: 17931529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
    Siebert U; Sroczynski G; Aidelsburger P; Rossol S; Wasem J; Manns MP; McHutchison JG; Wong JB
    Pharmacoeconomics; 2009; 27(4):341-54. PubMed ID: 19485429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to standards of quality HIV/AIDS care and antiretroviral therapy in the West Nile Region of Uganda.
    Burua A; Nuwaha F; Waiswa P
    BMC Health Serv Res; 2014 Nov; 14():521. PubMed ID: 25399661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.